Seroquel (quetiapine)

USES: Treatment of acute and chronic psychoses, including schizophrenia.

DOSAGE:'Seroquel' should be administered twice daily.

Titrate over 4 days to the recommended daily dose of 300 mg/day. However, adjust to patients requirements within the dose range 150 to 750 mg/day. In the elderly and in patients with known hepatic impairment (hepatically impaired patients should be started on 25mg/day),

'Seroquel' should be used with caution. Dosage titration and therapeutic dose depend on clinical response and tolerability of the individual patient.

Safety and efficacy of 'Seroquel' in children, not yet evaluated.

CONTRAINDlCATIONS: Hypersensitivity to 'Seroquel'.

PRECAUTIONS: Caution in patients with known cardiovascular disease, cerebrovascular disease or other conditions predisposing to hypotension and patients with a history of seizures.

Caution in combination with other centrally acting drugs and alcohol, and on coadministration with phenytoin, thioridazine or other enzyme inducers, potent inhibitors of CYP3A4 such as systemic ketoconazole and erythromycin. Pregnancy and lactation. Assess ability to drive and operate machinery.

SIDE EFFECTS: Asthenia, dry mouth, rhinitis, dyspepsia or constipation, mild somnolence and limited weight gain which occurs predominantly in the first few weeks, orthostatic hypotension (associated with dizziness, tachycardia and in some patients syncope). Occasional seizures. Rare NMS. Transient leucopenia and/or neutropenia. Asymptomatic, usually reversible elevations in AST, ALT or gamma-GT. Small elevations in nonfasting serum triglycerides and total cholesterol.

Decreases in thyroid hormone levels (particularly total T 4 and free T 4).

PRESENTATION: Film-coated tablets containing 25 mg, 100 mg, 150 mg or 200 mg quetiapine as free base.

'Seroquel'TM is a trademark, the property of AstraZeneca PLC.

Revised July 1998.
Consult full prescribing information before prescribing.

Further information available on request.

Alderley Park, Macclesfield, Cheshire, UK.

March 2000